ESR1 and breast carcinoma: However, the frequency of ESR1 mutations in treatment-naïve, de novo stage IV breast cancer patients was significantly higher than that of The Cancer Genome Atlas (TCGA) results that reported that the ESR1 genomic alteration in primary tumors was < 1%31.